Neurological abnormalities specialist Wave Neuroscience said on Thursday that it has closed the brain treatment technology asset purchase agreement with Newport Brain Research Laboratory (NBRL) for an undisclosed amount.
Under the terms of the agreement, Wave Neuroscience purchased substantially all of the assets from the various onshore and offshore holding companies under NBRL.
In conjunction with the acquisition, key NBRL personnel were appointed to new roles at Wave Neuroscience.
Since June, Wave Neuroscience has pledged more than USD500,000 of free treatments to US military members.
According to Wave Neuroscience, its research revolves around the premise that the brain can be treated by non-pharmaceutical and non-surgical means. It offers a personalised treatment platform for addressing neurological abnormalities and has treated more than 7,000 patients using its patented, non-invasive, drug-free MeRT process, which is licensed by a network of independently owned medical facilities.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA